Assistant Professor in Stem Cell Biology or RegenerativeBiology
Applications are invited for a tenure-track faculty position at thelevel of Assistant Professor in the Department of Developmental andCell Biology. We seek candidates with an interest in stem cell orregeneration biology, broadly defined. Applicants should pursueresearch in the major areas of interest of the department,including, but not limited to developmental biology, stem celland/or niche biology, regeneration and cancer stem cells. Prioritywill be given to candidates whose research will benefit frominterdisciplinary collaborations, interactions with members of thedepartment (http://devcell.bio.uci.edu), andfrom affiliation with campus centers and institutes.
The successful applicant is expected to conduct a vibrant researchprogram, contribute to the teaching and service missions of theUniversity of California, and share our commitment to diversity,equity and inclusion. Please send a curriculum vitae, 3-pagesummary of research accomplishments and goals, 1-page statement ofteaching and mentoring experience and philosophy, 1-page statementhighlighting past and/or potential contributions to diversity,equity and inclusion, and at least three letters of reference viathe online recruitment URL: https://recruit.ap.uci.edu/apply/JPF06561. Evaluation criteria for the research, teaching, and diversitystatements are provided at the online recruitment URL. Applicationscompleted by March 7, 2021 will be granted full consideration. Anyquestions about the suitability of an applicant for thisopportunity can be directed to the search chair, Peter Donovanpdonovan@uci.edu.
The UCI School of Biological Sciences is recognized as a nationalleader in the development of programs designed to increase theparticipation of underrepresented groups in the biomedical sciencesand is firmly committed to the ideals of equity, diversity, andinclusion (https://port.bio.uci.edu/about/,https://equity.bio.uci.edu). UCIis an Hispanic-Serving Institution, an Asian American and NativeAmerican Pacific Islander Serving Institution, and a chartermember of the AAAS SEA Change initiative that supportsinstitutional efforts to increase access and success for students,faculty and staff from groups marginalized in STEMM (https://www.aaas.org/news/four-new-charter-members-join-sea-change).Programs are available to meet the needs of dual-career academicpartners. Faculty are eligible for subsidized housing and aMortgage Origination Program. UC Irvine (https://uci.edu) is located 10 minutes fromthe coast (https://www.youtube.com/watch?v=82ARz3B60pU),is consistently ranked among the nations top 10 publicuniversities, and has recently been designated the #1 universitydoing the most for the American dream. The city of Irvine is hometo excellent parks, schools, entertainment opportunities, and adiverse citizenry.
The University of California, Irvine is an EqualOpportunity/Affirmative Action Employer advancing inclusiveexcellence. All qualified applicants will receive consideration foremployment without regard to race, color, religion, sex, sexualorientation, gender identity, national origin, disability, age,protected veteran status, or other protectedcategories covered by the UC nondiscrimination policy. A recipientof an NSF ADVANCE award for gender equity, UCI is responsive to theneeds of dual career couples, supports work-life balance through anarray of family-friendly policies, and is dedicated to broadeningparticipation in higher education.
The University of California is committed to creating andmaintaining a community dedicated to the advancement, application,and transmission of knowledge and creative endeavors throughacademic excellence, where all individuals who participate inUniversity programs and activities can work and learn together in asafe and secure environment, free of violence, harassment,discrimination, exploitation, or intimidation. With thiscommitment, as well as a commitment to addressing all forms ofacademic misconduct, UC Irvine conducts institutional referencechecks for candidate finalists to whom the department or otherhiring unit would like to extend a formal offer of appointment intoLadder Rank Professor or Professor of Teaching series, at all ranks(i.e., assistant, associate, and full). The institutional referencechecks involve contacting the administration of the applicantsprevious institution(s) to ask whether there have beensubstantiated findings of misconduct that would violate theUniversitys Faculty Code of Conduct. To implement this process, UCIrvine requires all candidates of Ladder Rank Professor orProfessor of Teaching series, at all ranks (i.e., assistant,associate, and full) to complete, sign, and upload the formentitled Authorization to Release Information into AP RECRUIT aspart of their application. If the candidate does not include thesigned authorization to release information with the applicationmaterials, the application will be considered incomplete. As withany incomplete application, the application will not receivefurther consideration. Although all applicants for facultyrecruitments must complete the entire application, only finalists(i.e., those to whom the department or other hiring unit would liketo extend a formal offer) considered for Ladder Rank Professor orProfessor of Teaching series, at all ranks (i.e., assistant,associate, and full) positions will be subject to institutionalreference checks.
REQUIREMENTS Curriculum Vitae Cover Letter Three letters of Reference Statement of Research Three pages.1. One page describing the significance and impact of your graduateand postdoctoral research.2. Two pages providing a plan for your future independent researchprogram that indicates how your research program will synergizewith the research environment at UCI (see e.g., https://www.bio.uci.edu/centers-institutes) Statement of Teaching One page.1. Describe any experience teaching/lecturing toundergraduates/graduate students or other populations and mentoringothers.2. Explain your teaching philosophy and describe how you willengage in teaching strategies that are effective in diversepopulations. Statement of Contributions to Diversity(http://www.uci.edu/diversity) One page.1. Indicate how you have demonstrated awareness of the issues facedby historically underrepresented or economically disadvantagedgroups and the benefits of a diverse and inclusive faculty.2. Provide evidence (if any) of your track record and success inactivities aimed at reducing barriers in education or research forunderrepresented or disadvantaged groups.3. Detail your specific plans (if any) to contribute through campusprograms, new activities, or through national or off-campusorganizations.
Link:
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments